Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Geron biopharmaceuticals, which provides treatment of cancer and chronic degenerative diseases, has appointed John Scarlett as the new CEO.
Subscribe to our email newsletter
Scarlett has an experience of over 25 years in the pharmaceutical and biotechnology industry.
Previously, he served as President and Chief Executive Officer of Proteolix, a biotechnology company developing proteasome inhibitors for oncology and immunology applications.
Scarlett has also been associated with comapnies like Tercica, Covance Biotechnology Services, North American Clinical Development Organization, Medical and Scientific Affairs at Novo Nordisk Pharmaceuticals and McNeil Pharmaceuticals.
Geron chairman Hoyoung Huh said that Geron wpild help in the continued transformation of the company towards significant value creation for its stockholders.